Bionano Genomics, Inc.
Close on Oct 19, 2026
- Market cap
- $14.09M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | During market hours | $8.20M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | $6.70M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $7.40M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | $6.70M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | $6.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $6.10M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 10, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue guidance | Full year 2026 | $31.00M to $33.00M | Raised |
| revenue guidance | Q3 2026 | $8.20M to $8.60M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Bionano Genomics filed with the SEC
September 14, 2026 Albert Luderer, PhD Chairman and Interim CEO Bionano
Regulation FD disclosure · EX-99.1 to Form 8-K
Bionano Reports Second Quarter 2026 Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Bionano Announces Hiring of Chief Scientific Officer
Other events · EX-99.1 to Form 8-K
Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
Other events · EX-99.1 to Form 8-K
Bionano Reports First Quarter 2026 Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
For more information, visit www.bionano.com or www.bionanolaboratories.com .
Executive or director change · Other events · EX-99.1 to Form 8-K
Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
Results of operations · EX-99.1 to Form 8-K
Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results
Results of operations · EX-99.1 to Form 8-K
Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
Results of operations · EX-99.1 to Form 8-K
Bionano Announces Effective Date of Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Bionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results
Results of operations · EX-99.1 to Form 8-K
Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bionano Announces Amendment to Senior Secured
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
Bionano Announces $3 Million Registered Direct Offering Priced At-
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bionano Announces Preliminary 3Q 2024 Revenues and Cash
Results of operations · EX-99.1 to Form 8-K
Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bionano Announces Private Placement of Senior Secured Notes in Debt Restructuring that Improves Balance Sheet
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
November 2023 Q3 2023 Financial Results Webcast & Call
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan
Material agreement · Results of operations · New financial obligation · Exit or restructuring costs · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Bionano Announces Pricing of $80.0 Million Registered Offering and Concurrent Private Placement of Senior Secured Convertible Notes and Warrants
Material agreement · Results of operations · New financial obligation · Exit or restructuring costs · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
Bionano Reports First Quarter 2023 Results and Highlights Recent Business Progress
Results of operations · EX-99.1 to Form 8-K
UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Bionano Genomics Reports Fourth Quarter and Full Year 2022 Results and Provides Revenue Outlook for 2023
Results of operations · EX-99.1 to Form 8-K
Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results
Results of operations · EX-99.1 to Form 8-K
+ Investor Call and Webcast November 29, 2022 Creating an End-to-End Solution
Other events · EX-99.1 to Form 8-K